The recent first-line FDA approval of the oral TKI zungertinib fundamentally alters the treatment paradigm for HER2-mutant non-small cell lung cancer. This shifts the standard of care away from initial platinum-based chemotherapy, forcing oncologists to reconsider the sequencing of TKIs, antibody-drug conjugates, and chemotherapy.
Unlike broader-spectrum tyrosine kinase inhibitors, zungertinib is highly selective for HER2 and avoids targeting wild-type EGFR. This specific mechanism is crucial as it leads to a better toxicity profile, particularly reducing the common EGFR-related side effects of rash and diarrhea, improving patient tolerability.
Data shows the next-generation KRAS G12C inhibitor deveracib achieves a median progression-free survival (PFS) of 13.8 months as a single agent. This represents a major leap forward, more than doubling the 5-6 month PFS seen with first-generation drugs like sotorasib and adagrasib, signaling a new efficacy benchmark.
The combination of deveracib and pembrolizumab shows remarkably high response rates (over 70%) and a promising 19.3-month median PFS in PD-L1 positive patients. This chemotherapy-free regimen demonstrates substantial activity even in PD-L1 negative patients, suggesting a potential paradigm shift away from chemotherapy for this common mutation.
The accelerated FDA approval of Taliso-V for CMET overexpression creates a new treatment category, distinct from previously targeted MET exon 14 skipping mutations. This validates IHC-based protein overexpression as an independent, actionable biomarker, expanding targeted therapy options for a new patient population that previously had none.